Major Adverse Cardiovascular Events in Patients with Melanoma Receiving Immune Checkpoint Inhibitors
Our results suggest that ICI might increase the risk of MACE in patients with melanoma during the first year after ICI.
Authors
- Anita Deswal (ORCID: https://orcid.org/0000-0002-6147-9591)
- Nicolas L. Palaskas (ORCID: https://orcid.org/0000-0001-7565-1797)
- Hui Zhao (ORCID: https://orcid.org/0000-0003-4742-1139)
- Maria Eugenia Suarez-Almazor (ORCID: https://orcid.org/0000-0001-5381-5797)
- Jennifer L. McQuade (ORCID: https://orcid.org/0000-0002-2393-2172)
- Bo Zhao (ORCID: https://orcid.org/0000-0002-2466-1343)
- Juan Ignacio Ruiz (ORCID: https://orcid.org/0000-0002-0885-134X)
Institutions
- The University of Texas MD Anderson Cancer Center (US)
Publication Details
- Journal
- Journal of Immunotherapy and Precision Oncology
- Published
- 2025-04-11
- DOI
- https://doi.org/10.36401/jipo-24-31
- Citations
- 1
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 1.05
Funders
- Duncan Family Institute for Cancer Prevention and Risk Assessment
- University of Texas MD Anderson Cancer Center